Corcept Therapeutics (CORT) announced the appointment of Roberto Vieira as President, Oncology. He will report to Joseph K. Belanoff, MD, Corcept’s CEO, and join the company’s Executive Team. Vieira joins Corcept from Mirati Therapeutics, (MRTX) where he served as Senior Vice President of U.S. Commercial until earlier this month.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CORT:
- Corcept Therapeutics price target lowered to $23 from $27 at Leerink
- Corcept Therapeutics price target raised to $61 from $50 at Ladenburg
- Corcept Therapeutics announces $200M stock buyback
- Corcept Therapeutics guides FY24 revenue at $600M-$630M, consensus $513.9M
- Corcept Therapeutics sees Q4 revenue at $135.4M, consnesus $127.9M
